InterContinental Mark Hopkins • San Francisco

Register before September 30th, 2010 and save!

Registration Information		Hotel Information	FREE Article Downloads
Individual Registration	Dealmaker's Package Registration	2010 Agenda	Sponsorship

Taking the Risk out of Asia: Top Pharma Leaders Share Best Practices

Benchmark your Asia strategies against the best and the brightest. 2010 PharmAsia speakers include:

Featured speakers include: Takeda's Investment Expansion Strategy in Asia Biogen Idec's Strategy in Asia Big Pharma Perspective: Comparing Emerging Markets Strategies Pre-Competitive Collaboration in Asia - A New Model for Sharing Risks, Reaping Rewards Graeme R Martin PhD President & CEO Takeda Research Investment Gunther Winkler PhD Senior VP Asia Pacific and Global Government Strategy Biogen Idec Ramesh Subrahmanian Senior VP & President of Asia Pacific Human Health Merck & Co. Neil W. Gibson PhD Chief Scientific Officer, Oncology Research Pfizer Catch Up on Asian Market Trends and Data The Asia Strategy for a Biotech Company: What is the Right Kind of Deal? Beyond Cost Arbitrage and More Shots on Goal: India Opportunity for Innovation Jan Willem Eleveld VP Consulting & Services Asia Pacific IMS Management Consulting Anthony Coles, MD, MPH CEO Onyx Pharmaceuticals Jan-Anders Karlsson, PhD CEO S*Bio (Singapore) Rashmi H. Barbhaiya CEO & Managing Director Advinus Therapeutics (Bangalore, India)

Experience Expert Insight From the Leading Asia Thought Leaders: Li Chen, PhD Former Head of Research & CSO Roche R&D Center China Charles Hsu, PhD, MBA Partner Bay City Capital Jonathan Wang, PhD, MBA Senior Managing Director, Asia OrbiMed Advisors Yi Chengdong Deputy Director General Shanghai FDA John Celebi VP, Business Development, New Products & Alliance Management ArQule Inc. George G. Montgomery Managing Director Montgomery Marshall Healthcare Partners Sanjiv Navangul, MBA, MSD Director - Chronic Care, Specialty, Care Disease Management India Merck & Co., Inc. (Mumbai, India) Hongbo Lu, PhD VP & Senior Research Analyst - China Healthcare Piper Jaffray Lee Byung-Keun CEO Green Cross (Seoul, Korea) Graeme Martin, PhD President & CEO Takeda Research Investment Utkarsh Palnitkar Executive Director Centrum Capital Bruce Ross India Office Director U.S. FDA Chris Hickey China Office Director U.S. FDA Jim Toole Senior Director, Oncology New Product Planning Daiichi Sankyo Chae Kyuhan Deputy Director of Pharmaceutical Safety Korea FDA Thomas Slater VP Commercial Development & International Cubist Pharmaceuticals

For complete agenda and list of speakers, click here

Western firms increasingly look at Asia as a major new market for their existing products and an inexpensive alternative venue for conducting clinical development and manufacturing operations. Representing nearly two-thirds of the world's population, this diverse powerhouse is expected to play a much larger role in coming decades in bringing innovative products to market.

As they get more involved in Asia, biopharma manufacturers are becoming more sophisticated about how they navigate in different countries. For larger companies, the efforts are not new, only they are more intense, with much greater commitment and resources behind them than in the past. The stakes are higher and companies must take a pragmatic, tactical perspective, even as they are drawn to the strategic opportunities. For small companies, engaging in Asia for the first time, with limited resources, means assessing accurately the intricacies of individual countries, as well as the best approaches to working in the region as a whole.

This year's PharmAsia Summit brings Asian, US and European industry leaders to San Francisco to share their experiences and help both those working directly in Asia and those situated in the West but involved in Asian operations or planning Asia strategy to better understand the myriad of complex challenges and equally attractive opportunities facing them.

BEYOND THE BASICS! PharmAsia Summit is the only event featuring marquee-level speakers and topics by the powerhouse editorial team from IN VIVO, Start-Up, "The Pink Sheet" and PharmAsia News.

Interested in learning more? Download the following PharmAsia-related articles for FREE! ArQule Signs c-Met Inhibitor, Discovery Platform Deals With Daiichi Sankyo Roche, OrbiMed And McKinsey’s Entrepreneurship Competition Builds Platform For China’s Young Biotech Community PPD’s Lee Babiss On Virtual R&D In China: An Interview With PharmAsia News (Part 1 Of 2) Compounds Discovered In Asia Expected To Enter Clinic In Three Years, Pfizer Says

PharmAsia Summit 2010 delivers the following sessions and more:

• Catch Up on Asian Market Trends and Data
• Biotech Perspective Biotech Perspective: Opportunities and Challenges In Asia
• Biogen Idec’s Strategy in Asia
• The Asia Strategy for a Biotech Company: What is the Right Kind of Deal?
• S*Bio (the largest Singapore Based Biotech)/Onyx (California) Deal: One of the Largest Biotech Deals in Asia
• Lessons Learned in Outsourcing: How Much Risk is Too Much?
• Building the Largest Biologics Contract Mfg Facility in Asia
• Grasping the Ins and Outs of Pricing, Market Access, IP Challenges in India
• Abbott’s $3.72 B Acquisition of Piramal Healthcare Solutions: How Abbott is Now the Largest Pharma Presence in India
• Merck’s Risk Sharing and Genzyme’s Malaria Deal
• Big Pharma Perspective: Comparing Emerging Markets Strategies: Acquisition vs. Organic growth?
• Betting on Different Models of Innovation in China: New Paths to New Products
• Comparing a Large Pharma’s Development Strategies and Capabilities vs. a CRO’s
• Expanding Roche’s Brick and Mortar Facility in China
• Incubating Innovative Product Companies Out of China
• Case Studies of New Models for Japanese Dealmaking
• Partnering with 2 Japanese Pharmas on the Same Compound: Daiichi-Sankyo and Kyowa Hakko Kirin
• Regulatory Risks: Market Access, Compulsory Licensing, Approvals and Data Exclusivity
• Hear from The Most Influential Regional FDA in China
• Investment Outlook For Asia: What Bets should you Make?
• Hear from One of the Top VCs in China on Its Many Investments
• Takeda’s Investment Expansion Strategy in Asia
• Commercializing your Drug in Asia: Case Studies on Marketing Authorization, Pricing, and Market Access
• Commercializing Januvia: Case Study in India
• Pre-Competitive Collaboration in Asia – A New Model for Sharing Risks, Reaping Rewards
• China Healthcare Reform: Who Will Benefit The Most?
• Working with Big Pharma to Help them Navigate the China Healthcare System
• Who will be the Winners and Losers from China’s Big Healthcare Reform


PLUS MUCH MORE!

Featuring THE Most Senior Level Business Development, R & D and Regulatory Strategists in the Industry

Hear all this in the U.S. – you don’t have to blow your travel budget flying to China and India. Asia leaders are coming here!

PharmAsia Summit is THE most strategic-level meeting where senior biotech and pharma executives share real-life case studies on how they’re building a presence in Asia – from drug development to market. PharmAsia Summit will gather the industry’s most senior leaders to share best practice case studies, successful business models and strategic partnerships from discovery to clinical trials. Join us for two days of interactive discussions, case studies and panels, and capitalize on Asia’s booming pharmaceutical market.

Here’s just a sample of companies that sent their teams in 2009!

Adjuvant Global Advisors, LLC Association of Biotechnology Led Enterprises (ABLE) 3S Bio, Inc. BayBio BayHelix Bio Foresight BioMarin Pharmaceutical BioPharma Today Burrill & Company Chinese-American BioPharmaceutical Society (CABS) Charles River Laboratories ChemPartner California Healthcare Institute Chinese Pharmaceutical Association Crown Bioscience CurrentPartnering Daylight Forensic & Advisory Dr. Reddy's Laboratories DSM Pharmaceutical Products Eli Lilly Global R&D, China Eli Lilly and Company Elsevier Business Intelligence EuroPharma Today US Food & Drug Administration (FDA) FDA CHINA Genentech Genomic Health Inc. Glaxosmithkline Greenleaf Health Llc Hutchison Medipharma Ltd. IN VIVO Johnson & Johnson Jubilant Biosys Jubilant Organosys Limited

LEAD Therapeutics Licensing Executives Society Lilly Singapore Centre for Drug Discover Merck & Co. Inc. Merck Research Laboratories Nishith Desai Associates OrbiMed Advisors Parexel PharmAsia News PharmaConnections Pharmalicensing.com Pfizer Pfizer China Piramal Life Sciences Procter & Gamble Pharmaceuticals Quintiles Roche Roche R & D Center Sanofi-Aventis Simcere Pharmaceutical Group Sino-American Biomedical and Pharmaceutical Association START-UP Susquehanna Financial Group Takeda Pharm Am Takeda Pharmaceuticals The Gold Sheet The Pink Sheet The Pink Sheet Daily Transcept Pharmaceuticals India Chamber of Commerce-USAIC Veeda Vertex Pharmaceuticals Wu Xi Apptec

Sponsorship Opportunities Available –Access the Most Senior-Level Decision-Makers at PharmAsia Summit

Why Attend PharmAsia Summit?

• Capitalize on potential new business and collaboration opportunities with the hottest Asian partners
• Network with hundreds of potential pharmaceutical and biotech partners through 1:1 meetings, cocktail parties, luncheons and refreshment breaks
• Hear about exciting new trends in Asian life sciences and dealmaking strategies
• Meet new partners and clients looking to expand capabilities in Asia
• Benchmark your Asia strategy against what your competitors are doing and why
• Maximize your strategic alliance opportunities by hearing CEOs, senior R&D and senior business development executives who share lessons learned, practical advice and strategies on how to build your R&D pipeline - both internally and externally
• Find out how to commercialize your product, valuate your alliances and develop a reimbursement strategy in Asia
• Hear expert panels about drug development in Asia — viewpoints from the top investigators in the field
• Hear only from handpicked sessions, by FDC/Windhover’s #1 editorial department (PharmAsia News, ”The Pink Sheet,” IN VIVO and Start-Up)
• Hone your dealmaking skills at our compelling plenary & keynote sessions from industry thought leaders on new trends and dealmaking strategies
• Find key new financing sources to fuel your growth
• Showcase your company’s products and services in front of the most active dealmakers — who are actively seeking you

Why sponsor PharmAsia Summit?

Windhover and PharmAsia News are making available a limited number of sponsorships in conjunction with this event, ensuring great visibility among a select number of companies. Here are just some of the reasons you should consider a PharmAsia Summit Sponsorship:

• China, India and emerging markets in Asia are the hottest regions for R&D and commercial growth for big pharma. PharmAsia Summit will attract senior-level executives in R&D, government & legal affairs, and business development & licensing from major pharmaceutical and biotechnology companies growing their business in this region. Associating your firm as a sponsor of the event ensures that key decision-makers recognize your brand as a leader in the region.
• PharmAsia Summit will attract some of the most notable names in the industry to speak candidly of the opportunities and challenges in China, India and emerging markets for biopharma. This assures that your brand is associated with an informative event that delivers real value to its attendees.
• PharmAsia Summit will attract senior executives from throughout the biotech and pharmaceutical industries, creating a rich dynamic of key decision-makers comparing notes on strategic issues that will impact everyone in the room. As a sponsor to this event, you will be regarded as a co-host to our intellectual gathering, reaping the benefits of high visibility and recognition as an industry thought leader

Sponsoring PharmAsia Summit provides unparalleled access to key decision-makers and today’s leading executives. Connect your organization to the most respected and knowledgeable health care information provider by sponsoring. Learn more.

	Sponsors
- Global Sponsors - - Gold Sponsors - - Silver Sponsor - - Regional Partners & Supporting Organizations - - Association Sponsors - - Major Supporting Publications - - Media Partners -